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BY-NC-ND license (http://creativecomAbstract Treatments with pegylated interferon/ribavirin (PEG-IFN/RBV) has been standard-
of-care in patients with chronic hepatitis C virus (HCV) (CHC) infection and reimbursed in
Taiwan. However, the actual cost-effectiveness remains unclear. We aimed to evaluate a
real-world cost-effectiveness for CHC patients treated with PEG-IFN/RBV by using a clinical
cohort with linkage to the National Health Insurance Research Database of Taiwan. The total
and itemized medical-care expenses of outpatient visits of 117 treatment-naı¨ve CHC patients
with linkage to the two million sampling of the National Health Insurance Research Database
were collected. Four components of costs were assessed, including antiviral agents, nonanti-
viral agents, laboratory testing and consultation costs. The cost per sustained virological
response (SVR) achieved was calculated to evaluate the cost-effectiveness. The average cost
per treatment in 117 naı¨ve Taiwanese CHC patients was $4620. With an overall SVR rate of
78.6%, the average cost per SVR was $5878. The average medical-care cost per treatment
for 52 Genotype 1 (G1) patients was $5133, including $4420 for antivirals, $380 for nonantivir-
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tients, the cost per SVR achieved was significantly higher in G1 patients than those in G2 pa-
tients ($7627 vs. $4799, p Z 0.001). In the current study, we provided the real-world cost-
effectiveness of PEG-IFN/RBV for treatment-naı¨ve CHC patients. The genotype-specific cost-
effectiveness could enhance decision-making for policy-makers in the coming era of directly
acting antiviral therapy.
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There are approximately 180 million people infected with
the hepatitis C virus (HCV) worldwide [1]. In Taiwan, a
recent study showed that around 0.6 million people are
chronically infected with HCV with a prevalence rate of
approximately 3.8% [2,3]. In the natural course of un-
treated HCV patients, 20% eventually develop liver
cirrhosis. Once cirrhosis is established, hepatocellular car-
cinoma (HCC) and hepatic decompensation will develop
with an incidence of 1e4% and 2e5%, respectively [4]. A
large community cohort study showed that the 18-year all-
cause mortality and specific mortality due to HCC were
30.1% and 10.4%, respectively, in the patients with HCV
viremia [5]. Successful antiviral therapy has been associ-
ated with greater reduction of liver cirrhosis, HCC, and
liver-related mortality [6e9].
Pegylated interferon (PEG-IFN) plus ribavirin (RBV)
combination therapy has been the standard-of-care in the
past two decades, which could achieve high sustained
virological response (SVR) rates in Taiwan. A 48-week or 24-
week regimen of peg-IFN-a (PEG-IFN-a2a or PEG-IFN-a2b)
plus RBV could achieve an SVR rate of 70e75% and 85e90%
for HCV Genotype 1/4 (HCV-1/4) and HCV-2/3, respec-
tively, in Taiwan [10e12]. However, PEG-IFN/RBV might
cause significant adverse events, dose reduction, and early
discontinuation in the treatment of chronic hepatitis C
(CHC) [13], leading to a huge gap between high clinical
efficacy (80%) and low community effectiveness (13%) in
Taiwan [3]. Recently, the introduction of new directly
acting antiviral agent (DAA) regimens (mostly IFN-free)
greatly improved the treatment efficacy and reduced the
adverse events [14e16]. However, DAAs are expensive [17]
and necessitate a cost-effectiveness analysis to compare
the different regimens for the treatment of HCV, especially
in countries where PEG-IFN/RBV could provide high treat-
ment efficacy, such as Taiwan and East Asia [10]. Never-
theless, most of the cost-effectiveness analysis only
counted the cost of antivirals without taking the other
costs, such as nonantivirals and laboratory tests, into
consideration [18e25]. Therefore, a real-world cost-effec-
tive analysis including all of the real-world costs is very
important to provide the evidence for decision-making of
nation-level policy.
In Taiwan, the National Health Insurance Program, with
coverage rate up to 99.6% population, provides compre-
hensive database for real-world cost-effectiveness analysis
[26]. We hereby conducted a real-world cost-effectivenessai P-C, et al., A real-world impac
s C patients in Taiwan, Kaohsiunganalysis for CHC patients treated with PEG-IFN/RBV based
on the National Health Insurance Research Database
(NHIRD) in Taiwan.Methods
Study population
In the hospital-based cohort study, a total of 4740 CHC
patients receiving PEG-IFN/RBV regimens were consecu-
tively enrolled in a medical center and two core regional
hospitals from 1991 to 2014. All consecutive treatment
courses with available on-treatment clinical data were
assessed. Patients who had HCC before antiviral treatment,
with hepatitis B virus dual infections or human immuno-
deficiency virus dual infection, were excluded. Therefore,
3781 CHC patients were enrolled in this further study.
All patients were provided written informed consent.
The institutional review board at the participating hospitals
approved the protocols, which conformed to the guidelines
of the International Conference on Harmonization for Good
Clinical Practice costs.
Clinical data (laboratory examinations and SVR
assessment)
Serum HCV RNA was detected using qualitative real-time
polymerase chain reaction (COBAS AMPLICOR HCV Test, ver.
2.0; Roche, Branchburg, NJ, USA) and quantification
branched DNA assay (Versant HCV RNA 3.0, Bayer, Tarry-
town, NJ, USA; quantification limit: 615 IU/mL). The HCV
genotypes were determined using the Okamoto method
[27]. The liver histology, which was obtained within 1 year
before antiviral therapy, was graded and staged according
to the scoring system described by Scheuer [28].
The treatment efficacy, SVR, was defined as seronega-
tivity of HCV RNA throughout a 24-week post-antiviral
treatment follow-up period.
Cost measurement from NHIRD
Costs were sourced from real-world retrospective HCV
clinic data to link the 2 million sampling of NHIRD during
1998e2011. The 2 million sampling of NHIRD derived from
the universal compulsory national health insurance pro-
gram, which was conducted by the Taiwan government int of cost-effectiveness of pegylated interferon/ribavarin regimens
Journal of Medical Sciences (2016), http://dx.doi.org/10.1016/
4740 CHC patients
Excluded 
ID missing 
HCC 
HBsAg +3365 Naïve
416 Experienced
Two million sampling NHIRD out patients 
expenditure and order
from 2000 to 2011
305 Naïve
36 Experienced
Excluded 
Start date of treatment later than January 1, 2011
Out of 3 mo before treatment and 6 mo after treatment  
No PegIFN/RBV drugs using 
SVR information missing
Treatment experienced
117 Naïve
Figure 1. Study cohort enrolled. CHC Z chronic HCV;
HCC Z hepatocellular carcinoma; NHIRD Z National Health
Insurance Research Database; PEG-IFN Z pegylated inter-
feron; RBV Z ribavirin; SVR Z sustained virological response.
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eleventh of the total 23 million of the national population.
The four components of medical-care in outpatient
clinics were: medication (antiviral agents and nonantiviral
agents) costs, laboratory testing costs, and consultation
costs. All of the costs were based on the records of pre-
scribed medication, laboratory tests, and consultation
retrieved from linked NHIRD. The assessed period for the
medical care costs was retrieved from 3 months before
starting antiviral treatment to 6 months after stopping
antiviral treatment. All medical costs were expressed in US
Dollars with a currency rate at 32 New Taiwan Dollars to US
$1.
Statistical analyses
Number/percentage and mean/standard deviation were,
respectively, presented in the calculation of SVR rate and
medical-care costs. The average total cost per SVR ach-
ieved was calculated as (the summation of total cost for all
HCV-treated patients)/number of SVR cases. The average
cost per SVR will be additionally performed by HCV geno-
type. All analyses will be conducted by SAS software (SAS
Institute Inc., Carey, NC, USA). All statistical analyses were
based on two-sided hypothesis tests with a significance
level of p < 0.05.
Results
Patients profile
A total of 3781 CHC patients (3365 naı¨ve and 416 treatment)
were initially enrolled in this study. After linking to two
million outpatient expenditure and order of NHIRD, we used
the five criteria to screen targeting outpatient visits: (1) the
date of outpatient visits was not located on the assessed
HCV management period; (2) treatment starting date later
than January 1, 2011, due to limited NHIRD dataset; (3)
patients did not use PEG-IFN/RBV drugs on each visit; (4)
there was no SVR information; and (5) patients who were
treatment-experienced. Patients who met the criteria lis-
ted above were excluded in the further outpatient-cost
analysis. Finally, 117 treatment-naive CHC patients were
enrolled for further analysis (Figure 1).
The basic demographical, virological, and histological
features are shown in Table 1. A total of 92 (78.6%) of 117
patents achieved an SVR with a mean follow-up period of
27.1 weeks, whereas 25 (21.4%) patients treated failure
with a longer follow-up period of 32.1 weeks. The mean age
was 50.2 years for patients with SVR and 55.5 years for
patients without SVR. Males accounted for 53.3% of the
patients with SVR and 36.0% of the patients without SVR.
The percentages of patients in the groups of Fibrosis F0e2,
F3e4 were 76.4% and 23.6% for patients with SVR and 76.2%
and 23.8% for patients without SVR. The mean HCV RNA was
5.4 (KIU/mL) for patients with SVR and 5.8 (KIU/mL) for
patients without SVR. In addition, the frequency of HCV
genotype distribution was significantly different between
the patients with SVR and without SVR. Some 62% of SVR
patients were HCV Genotype 2 and 68% of non-SVR patients
were HCV Genotype 1 (p Z 0.0075).Please cite this article in press as: Tsai P-C, et al., A real-world impac
on treatment-naı¨ve chronic hepatitis C patients in Taiwan, Kaohsiung
j.kjms.2016.10.008Cost analysis
The average medical-care cost per treatment was $4620
(standard deviation, 1537), including $3984 for antivirals,
$345 for nonantivirals, $264 for laboratory testing, and $65 for
consultation (Supplementary Table 1). The average cost per
treatment was higher in non-SVR patients when compared to
that in SVR patients ($4810 and $4569, respectively, Table 1).
Since HCV genotype is the most important predictor of
the HCV treatment efficacy to PEG-IFN/RBV, we further
analyzed the cost-effectiveness according to the viral ge-
notype. Among the 117 treatment-naı¨ve CHC patients,
there were 52 HCV Genotype 1 (G1) and 65 Genotype 2 (G2)
patients. The SVR rate was 67.3% in G1 patients, which was
significantly lower than 87.7% in G2 patients (p Z 0.012).
The average medical-care cost per treatment for G1 pa-
tients was $5133 (standard deviation, 1589) including $4420
for antivirals, $380 for nonantivirals, $302 for laboratory
testing, and $78 for consultation, compared to $4209,
$3635, $317, $233, and $56, respectively, for G2 patients
(p Z 0.0038 for antivirals, p Z 0.47 for nonantivirals,
p Z 0.018 for laboratory testing, and p Z 0.016 for
consultation). Among these medical-care costs, the anti-
viral cost, laboratory testing, and consultation cost per
treatment for G1 patients were significantly higher than
those for G2 patients. The medical-care cost per treatment
for G1 patients was $4913 and $5239 for non-SVR and SVR
patients, respectively. By contrast, the medical-care cost
per treatment for G2 patients was $4582 and $4157 for non-
SVR and SVR patients, respectively (p Z 0.49 for G1,
p Z 0.42 for G2) (Supplementary Table 1).t of cost-effectiveness of pegylated interferon/ribavarin regimens
Journal of Medical Sciences (2016), http://dx.doi.org/10.1016/
Table 1 Baseline clinic demographic profiles of CHC patients.
n SVRa p
Yes (n Z 92) No (n Z 25)
Age < 60 y 94 77 (83.7) 17 (68.0) 0.10
 60 y 23 15 (16.3) 8 (32.0)
Sex Female 59 43 (46.7) 16 (64.0) 0.18
Male 58 49 (53.3) 9 (36.0)
Fibrosis scoreb 0e2 58 42 (76.4) 16 (76.2) 0.99
3e4 18 13 (23.6) 5 (23.8)
AST (IU/L) 117 93.6  53.8 102.3  46.3 0.46
ALT (IU/L) 117 148.1  88.0 158.1  91.0 0.62
HCV RNA (KIU/mL) 117 5.4  0.9 5.8  0.7 0.09
HCV genotype Genotype 1 52 35 (38.0) 17 (68.0) 0.0075
Genotype 2 65 57 (62.0) 8 (32.0)
Treatment duration (wk) 117 27.1  11.1 32.1  12.3 0.06
Cost per treatment (US $) 117 4569  1417 4810  1941 0.49
Cost per SVR (US $) 117 5878  1955
a Data are presented as n (%) or mean  SD.
b Forty-one patients had no liver histology available.
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We further analyzed the cost per SVR achieved. For all
naı¨ve patients with an SVR rate at 78.6%, the cost per SVR
achieved was $5878 (standard deviation, 1955) (Table 1).
With an SVR rate at 67.3% for G1 and 87.7% for G2 patients,
the cost per SVR achieved was $7627 (standard deviation,
2361) and $4799 (standard deviation, 1566) for G1 and G2
patients, respectively (p < 0.001) (Table 2). The average
itemized cost per SVR for G1 patients was $6568 for anti-
virals, $565 for nonantivirals, $449 for laboratory testing,Table 2 The number/percentage and average cost per
sustained virological response (SVR) achieved (US $) on
hepatitis C virus (HCV) genotype 1 and HCV genotype 2
patients stratified by age, sex and liver fibrosis.
No. (%) Average
cost per
SVR (US $)
All
patients
Non-SVR SVR
Naı¨ve G1 52 17 (32.7) 35 (67.3) 7627
Age < 60 y 42 12 (28.6) 30 (71.4) 7,313*
 60 y 10 5 (50.0) 5 (50.0) 9,510*
Sex Female 28 10 (35.7) 18 (64.3) 8,074
Male 24 7 (29.1) 17 (70.8) 7,152
Fibrosis 0e2 30 7 (30.0) 21 (70.0) 6,182**
3e4 8 4 (50.0) 4 (50.0) 10,099**
Naı¨ve G2 65 8 (12.3) 57 (87.7) 4,799
Age < 60 y 52 5 (9.6) 47 (90.4) 4,835
 60 y 13 3 (23.1) 10 (76.9) 4,647
Sex Female 31 6 (19.3) 25 (80.7) 5,093
Male 34 2 (5.9) 32 (94.1) 4,569
Fibrosis 0e2 28 7 (25.0) 21 (75.0) 5,686
3e4 10 1 (10.0) 9 (90.0) 4,351
* p Z 0.0004.
** p < 0.0001.
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and $64, respectively for G2 patients (p < 0.0001 for anti-
virals, p Z 0.074 for non-antivirals, p < 0.0001 for labo-
ratory testing, p < 0.0001 for consultation) (Figure 2).
Among naı¨ve G1 patients, younger age and mild hepatic
fibrosis had significantly better real-world cost effective-
ness to PEG-IFN/RBV therapy when compared to their
counterparts (p Z 0.0004 for age < 60 vs.  60 and
p < 0.0001 for fibrosis 0e2 vs.3e4). However, there was no
group-specific difference of cost-effectiveness in naı¨ve G2
patients, in terms of age, sex and hepatic fibrosis (Table 2).
Discussion
In this present study, we provided the real-world cost-
effectiveness of PEG-IFN/RBV in Taiwan. The average cost
per SVR achieved was $5878. When stratified according to
viral genotype, the results showed that the cost per SVR of
$7627 in G1 CHC patients was 1.5 fold of $4799 in G2 CHC
patients. Among these medical-care costs, the antiviral
cost, laboratory testing, and consultation cost per treat-
ment for G1 patients was significantly higher than those for
G2 patients.
Interestingly, the cost per treatment between SVR and
non-SVR patients was paradoxical between HCV G1 and G2
patients. HCV G1 non-SVR patients had lower cost of
medical-care costs, antiviral agents and nonantiviral
agents, and higher costs of laboratory testing than HCV G1
SVR patients. By contrast, almost of the components of
medical-care cost were higher in HCV G2 non-SVR than HCV
G2 SVR patients. The standard care of HCV G1 patients with
PEG-IFN/RBV is 48 weeks. Nevertheless, around 5e10% of
HCV G1 patients could not achieve an early virological
response at week 12, for whom early termination of PEG-
IFN/RBV treatment was recommended due to little chance
of achieving an SVR [10]. This might therefore lead to the
lower costs for HCV G1 non-SVR patients. However, most of
the HCV G2 patients could achieve a rapid virologicalt of cost-effectiveness of pegylated interferon/ribavarin regimens
Journal of Medical Sciences (2016), http://dx.doi.org/10.1016/
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Figure 2. Antiviral and nonantiviral agents cost, laboratory testing cost, and consultation cost (US $) and effectiveness evaluated
as sustained virological response (SVR) on treatment naı¨ve, hepatitis C virus (HCV) Genotype 1 and HCV Genotype 2.
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ened to 16 weeks do not compromising the treatment ef-
ficacy [12].
As expected, the average cost per SVR was much higher
in HCV G1 patients than in HCV G2 patients ($7627 vs.
$4799, respectively, in Taiwan). This was due to a longer
period of antiviral therapy and lower SVR rate in HCV G1
patients when compared to HCV G2 patients. Thus, at our
real-world medical-care costs, the PEG-IFN/RBV had much
better cost-effectiveness in the treatment of HCV G2 than
in the HCV G1 patients. We demonstrated that not only
antiviral agents, but also nonantiviral agents, laboratory
testing, and consultation costs were higher in HCV G1 pa-
tients than in HCV G2 patients. This indicated longer
treatment duration, more adverse events, and outpatient
visits in HCV G1 patients than in HCV G2 patients.
There were limitations in this study. First, the result was
preliminary as it connects the 2 million out of 23 million
patient profiles, which was one-eleventh of the Taiwan
whole population. However, the randomized sampling will
reduce the bias. Secondly, our analysis was limited to direct
medical-care costs; indirect costs such as lost productivity
and caregiver salaries were not hard to assess and not
included in the present study.
In this study, we provided the real-world cost-effective-
ness of PEG-IFN/RBV according to viral genotype. Our results
enhance the formation of a future strategy of HCV therapy
for policy-makers in the era of DAA IFN-free therapy.
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